An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2018
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Therapeutic Use
- 18 Jul 2018 Planned End Date changed from 31 Dec 2019 to 31 Aug 2018.
- 18 Jul 2018 Status changed from suspended to active, no longer recruiting.
- 01 Feb 2018 Planned End Date changed from 31 Mar 2018 to 31 Dec 2019.